Affordable Access

A randomized study comparing fluconazole with amphotericin B/5-flucytosine for the treatment of systemic Candida infections in intensive care patients.

Authors
  • Abele-Horn, M
  • Kopp, A
  • Sternberg, U
  • Ohly, A
  • Dauber, A
  • Russwurm, W
  • Büchinger, W
  • Nagengast, O
  • Emmerling, P
Type
Published Article
Journal
Infection
Publication Date
Jan 01, 1996
Volume
24
Issue
6
Pages
426–432
Identifiers
PMID: 9007589
Source
Medline
License
Unknown

Abstract

In this prospective, randomized study fluconazole and amphotericin B/5-flucytosine were compared in the treatment of systemic candidiasis. Seventy-two non-neutropenic intensive care patients with systemic Candida infections were enrolled. Thirty-six patients were randomly assigned to receive fluconazole (400 mg on the first day then 200 mg) and 36 were randomized to amphotericin B/5-flucytosine (1.0-1.5 mg/kg body weight every other day and 3 x 2.5 g flucytosine/day) for 14 days following the diagnosis. There was no statistically significant difference in clinical outcome in regard to the treatment of pneumonia and sepsis: 18/28 of the patients were treated successfully with fluconazole and 17/27 with amphotericin B/5-flucytosine. For the treatment of peritonitis, however, amphotericin B/5-flucytosine was more effective than fluconazole (55% vs. 25%). Furthermore, amphotericin B/5-flucytosine was found to be superior to fluconazole with regard to pathogen eradication (86% vs. 50%). Fluconazole was associated with less toxicity than amphotericin B/5-flucytosine.

Report this publication

Statistics

Seen <100 times